Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer Clinical Trial

Official title:

A Randomized Phase 2 Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00617734
• Other study ID #: 13913
• Secondary ID: CP13-0706CP02-07
• Status: Completed
• Phase: Phase 2
• First received: January 30, 2008
• Last updated: March 17, 2018
• Start date: March 2008
• Est. completion date: July 2012

Study information

• Verified date: March 2018
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had disease progression and platinum-containing chemotherapeutic regimen.

Description:

The routine cancer treatments for Squamous Cell Carcinoma Head and Neck Cancer have improved but still leave a percentage of participants with incurable disease. New alternatives for participants whose disease is refractory to existing therapies is needed.

IMC-A12 is a monoclonal antibody which binds to special receptors known as insulin-like growth factor-I receptor (IGF-IR). This binding action has been shown to inhibit the growth of a variety of human tumor cell lines.

The purpose of this study is to evaluate the effects of IMC-A12 by itself or with Cetuximab (Erbitux®) in participants with Squamous Cell Carcinoma Head and Neck Cancer that has spread to other parts of the body, and to determine how long the drug remains in the body. The study will also look at what side effects IMC-A12 may cause when a participant is receiving treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 97
• Est. completion date: July 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically-confirmed squamous cell carcinoma of the oropharynx, hypopharynx, larynx, or oral cavity, metastasis or recurrence documented by clinical imaging studies

• Measurable disease, lesion size = 2 centimeters (cm) on conventional measurement techniques or = 1 cm on spiral computed tomography (CT) scan

• Clinical documentation of disease progression during treatment with or within 90 days after receiving the last cycle of platinum-based chemotherapy (with or without radiation therapy)

• If prior treatment with anti-epidermal growth factor receptor (EGFR) therapy, the time to recurrence from last exposure to anti-EGFR therapy is > 90 days

• Adequate hematologic function

• Adequate hepatic function

• Adequate coagulation function or is on a stable dose of an anticoagulant.

• Adequate renal function

• Fasting serum glucose <120 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN)

• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation

Exclusion Criteria:

• Not recovered from adverse events due to agents administered more than 4 weeks earlier. Neurotoxicity, must have recovered to grade = 2

• Is receiving any other investigational agent(s)

• History of treatment with other agents targeting the insulin-like growth factor receptor (IGFR)

• Is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemoembolization, or targeted therapy

• History of allergic reactions attributed to compounds of chemical or biologic composition similar to those of cetuximab or IMC-A12

• Has poorly controlled diabetes mellitus. Participants with a history of diabetes mellitus are allowed to participate, provided that their blood glucose is within normal range (fasting < 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition

• Pregnant or breastfeeding

• Is receiving therapy with immunosuppressive agents

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Biological:
• IMC-A12 (cixutumumab)
IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
• cetuximab (Erbitux ®)
IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.

Locations

Country	Name	City	State
United States	ImClone Investigational Site	Atlanta	Georgia
United States	ImClone Investigational Site	Baltimore	Maryland
United States	ImClone Investigational Site	Boston	Massachusetts
United States	ImClone Investigational Site	Bronx	New York
United States	ImClone Investigational Site	Charlottesville	Virginia
United States	ImClone Investigational Site	Chicago	Illinois
United States	ImClone Investigational Site	Houston	Texas
United States	ImClone Investigational Site	Miami	Florida
United States	ImClone Investigational Site	Nashville	Tennessee
United States	ImClone Investigational Site	New York	New York
United States	ImClone Investigational Site	Orange	California
United States	ImClone Investigational Site	Orlando	Florida
United States	ImClone Investigational Site	Pittsburgh	Pennsylvania
United States	ImClone Investigational Site	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival (PFS)	PFS was defined as the interval from randomization until PD or death, whichever occurred first. Response was defined using Response Evaluation Criteria in Solid Tumors (RECIST, version 1.0) criteria. PD was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. PFS was censored at the date of the last objective progression-free disease assessment for participants who did not experience PD or death.	Baseline to measured PD (up to 27.66 months)
Secondary	Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]	ORR was defined as the percentage of participants achieving either CR or PR. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants is calculated as a total number of participants with CR or PR divided by the total number of participants treated then multiplied by 100.	Baseline to measured PD (up to 27.66 months)
Secondary	Percentage of Participants With PFS at 6 Months	PFS at 6 months was defined as the percentage of participants who have neither experienced PD nor died at 6 months after the date of randomization. Response was defined using RECIST, version 1.0 criteria. PD was defined as having at least a 20% increase in sum of the longest diameter of target lesions or the appearance of new lesions. Percentage of participants is calculated as the total number of participants with PFS at 6 months divided by the total number of participants treated then multiplied by 100.	6 months
Secondary	Overall Survival (OS)	OS was defined as the duration from the date of randomization to the date of death from any cause. For participants who were alive, OS was censored at the date of last follow-up visit or at the date of last contact.	Baseline to date of death from any cause (up to 29.63 months)
Secondary	Duration of Response	The duration of CR or PR was defined as the time from first objective status assessment of CR or PR to the first time of PD or death. Response was defined using RECIST, version 1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Duration of response was censored on the date of last tumor assessment for participants who were alive and have no evidence of PD.	Date of first response to the date of PD or death due to any cause (up to 23.98 months)
Secondary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Deaths	TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). Data presented are the number of participants who experienced TEAEs including serious TEAEs, and deaths during the study including the 30-day follow-up. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events section of this report.	Baseline through study completion (up to 29.63 months)
Secondary	Blood And Tissue Biomarkers And Development of Serum Antibodies Against IMC-A12 and Cetuximab	No data for biomarkers and serum antibodies were collected due to lack of an appropriate validated assay.	Biomarkers [pre-dose, Cycle 1 (Day 15), (Cycle 2 (Day 1), and end of treatment]; Immunogenicity [pre-dose, prior to first infusion for Cycle 3, Cycle 5, and 30-day safety follow-up]